Publications by authors named "Jaka Bon"
Objectives: The implementation of disease-modifying treatments for Alzheimer's Disease (AD) will require cost-effective diagnostic processes. As part of The Precision Medicine In AD consortium (PMI-AD) project, the aim is to analyze the baseline costs of diagnosing early AD at memory clinics in Norway, Slovenia, and the Netherlands.
Methods: The costs of cognitive testing and a clinical examination, apolipoprotein E, magnetic resonance imaging (MRI), cerebrospinal fluid (CSF), positron emission tomography and blood-based biomarkers (BBM), which are used in different combinations in the three countries, were analyzed.
Article Synopsis
- The MOPEAD project aims to improve the detection and diagnosis of Alzheimer's disease (AD) through various patient-engagement strategies across five European countries.
- Four screening methods were tested: a web approach, Open-House initiatives, screenings in primary care, and by diabetes specialists, with results showing different costs per true-positive (TP) diagnosis for each method.
- Primary care and diabetes specialists were the most cost-effective methods for diagnosing AD, but their ability to identify at-risk patients effectively raises questions, suggesting a potential need for refined web and Open-House strategies.
Article Synopsis
- General practitioners (GPs) are crucial for early dementia detection, but often fail to diagnose it on time, prompting a study on their attitudes and barriers in five European countries.
- Out of 343 GPs surveyed, 74% believe early diagnosis is important, but opinions vary by country regarding reimbursement and consultation time for patients.
- If an effective drug for slowing Alzheimer’s progression were available, 59% of GPs indicated they would change how they approach early diagnosis, highlighting the impact of treatment options on diagnostic practices.